United Therapeutics Corp.
1110 Spring Street
Silver Spring,
MD 20910
Phone: 301-608-9292
Fax: 301-608-9291
Web Site: http://www.unither.com
| United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases. It offers product primarily in three therapeutic areas, including cardiovascular, cancer, and infectious diseases. The company's products include Remodulin for Pulmonary arterial hypertension; Arginine formulations for vascular function; CardioPAL and Decipher Recorders for arrhythmias and ischemic heart disease; OvaRex, which is in phase III trials, for the treatment of ovarian cancer; Viveta, which is in phase III trials, for pulmonary arterial hypertension; UT-15C, which is in phase II/III trials for pulmonary arterial hypertension, as well as in phase II trials for peripheral vascular disease/critical limb ischemia; Remodulin, which is in phase II trials, for improved transplant outcome; Beraprost, which is in phase I, for pulmonary arterial hypertension; BrevaRex, which is in preclinical stage, for pancreatic cancer; Glycobiology antiviral agents, which is in preclinical stage, for hepatitis B/C, dengue fever, and Japanese encephalitis; OncoRex, which is in preclinical stage, for various cancers; ProstaRex, which is in preclinical stage, for prostate cancer; and GivaRex, which is in preclinical stage, gastrointestinal cancer. It also offers a range of telemedicine services to detect cardiac arrhythmias and ischemic heart disease. The company has operations primarily in the United States, Europe, and Asia. United Therapeutics Corporation has strategic alliance with Medtronic MiniMed for the use of pager-sized continuous microinfusion pump for delivery of Remodulin subcutaneously. The company was founded in 1996 and is headquartered in Silver Spring, Maryland. |
|
| Key Statistics |
|
|
|
| |
Pay |
Exercised |
Ms. Martine Rothblatt Ph.D, J.D., 53
Founder, Chairman and Chief Exec. Officer
|
$
1.02M |
$
4.51M |
Dr. Roger Jeffs Ph.D., 46
Pres, Chief Operating Officer
|
$
860.00K |
$
5.50M |
Mr. John M. Ferrari , 53
Chief Financial Officer and Treasurer
|
$
249.00K |
N/A |
Mr. Paul A. Mahon J.d., 44
Exec. VP of Strategic Planning, Gen. Counsel and Corp. Sec.
|
$
680.00K |
$
3.63M |
Dr. Stuart Rich M.D.,
Chief Medical Officer
|
N/A
|
N/A |
|
|
|
Dollar amounts are as of
31-Dec-06
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
|
|
|
Help
0.79 (1.77%) 
Profile
